Teachers Retirement System of The State of Kentucky Trims Stake in Lantheus Holdings, Inc. $LNTH

Teachers Retirement System of The State of Kentucky trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,321 shares of the medical equipment provider’s stock after selling 19,494 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Lantheus were worth $1,042,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LNTH. Hantz Financial Services Inc. increased its stake in shares of Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus in the second quarter valued at about $26,000. First Horizon Corp purchased a new stake in Lantheus in the third quarter worth about $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the 2nd quarter worth about $36,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Lantheus during the 3rd quarter worth about $59,000. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on LNTH shares. Truist Financial boosted their price target on shares of Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a report on Friday, February 27th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Citizens Jmp lifted their price objective on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a report on Tuesday, February 24th. Mizuho boosted their price objective on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th. Finally, Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $82.17.

Lantheus Stock Performance

Shares of Lantheus stock opened at $72.56 on Friday. The company has a market capitalization of $4.69 billion, a PE ratio of 21.53 and a beta of -0.11. The company has a 50-day simple moving average of $69.11 and a two-hundred day simple moving average of $60.90. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. The business had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company’s revenue was up 4.0% compared to the same quarter last year. During the same period last year, the business earned $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.